Birch Pollen Allergy - Pipeline Review, H1 2019

Birch Pollen Allergy - Pipeline Review, H1 2019


  • Products Id :- GMDHC11089IDB
  • |
  • Pages: 42
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Birch Pollen Allergy-Pipeline Review, H1 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Birch Pollen Allergy-Pipeline Review, H1 2019, provides an overview of the Birch Pollen Allergy (Immunology) pipeline landscape.

Birch pollen allergy is a reaction which occurs soon after exposure to pollen of birch trees. Signs and symptoms include skin reactions, such as hives, redness or swelling, itching or tingling in or around the mouth and throat, digestive problems, such as diarrhea, stomach cramps, nausea or vomiting, tightening of the throat, shortness of breath or wheezing and runny nose. Predisposing factors include age, family history and other allergies. Treatment includes drugs belonging to class of antihistamines.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Birch Pollen Allergy-Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Birch Pollen Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Birch Pollen Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Birch Pollen Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Preclinical and Discovery stages are 2, 2, 3 and 2 respectively.

Birch Pollen Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Birch Pollen Allergy (Immunology).

- The pipeline guide reviews pipeline therapeutics for Birch Pollen Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Birch Pollen Allergy (Immunology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Birch Pollen Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Birch Pollen Allergy (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Birch Pollen Allergy (Immunology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Birch Pollen Allergy (Immunology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Birch Pollen Allergy-Overview

Birch Pollen Allergy-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Birch Pollen Allergy-Therapeutics Assessment

Assessment by Route of Administration

Assessment by Molecule Type

Birch Pollen Allergy-Companies Involved in Therapeutics Development

ALK-Abello AS

Allergy Therapeutics Plc

Anergis SA

Biomay AG

Desentum Oy

HAL Allergy BV

Laboratorios LETI SL

S-TARget therapeutics GmbH

Birch Pollen Allergy-Drug Profiles

Allergen for Allergic Rhinitis, Allergic Rhino-Conjunctivitis and Birch Pollen Allergy-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Birch Pollen Induced Allergic Rhinoconjunctivitis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

birch pollen allergen extract-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BM-31-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PL-102-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pollinex Quattro Birch-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SG-300-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Birch Pollen Allergy-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccines For Birch Pollen Allergy-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Birch Pollen Allergy-Dormant Projects

Birch Pollen Allergy-Discontinued Products

Birch Pollen Allergy-Product Development Milestones

Featured News & Press Releases

Dec 13, 2018: Anergis reports positive preclinical proof-of concept data of the Second-Generation COP Allergy Vaccine

Sep 05, 2018: Anergis initiates development of second-generation COP Allergy Vaccines; announces publication of sustained efficacy data from Ph. IIb study follow-Up

Aug 14, 2018: HAL Allergy first company to achieve marketing authorisations in line with Therapieallergene-Verordnung (TAV) in Germany

May 27, 2018: Allergy experts: Clinical effect of ALK's tree SLIT-tablet among the most significant ever seen in allergy immunotherapy trials

Jun 14, 2017: Desentum has two presentations in EAACI 2017

May 10, 2017: Desentum is preparing to start clinical trials with birch pollen allergy vaccine

Mar 16, 2017: Allergy Therapeutics Announces First Patient Recruited in Pivotal Phase III Birch Immunotherapy B301 Study

May 17, 2016: HAL Allergy has successfully completed its Phase III short-term efficacy trial with its sublingual allergen immunotherapy (SLIT) liquid product for the treatment of birch pollen allergy

May 09, 2016: Allergy Therapeutics Announces Positive Top-Line Results From the PQBirch204 Phase II Study for Birch-Induced Seasonal Allergic Rhinitis

Sep 01, 2015: First patient recruited in Pollinex Quattro Birch dose ranging study in Germany and Austria

Mar 10, 2015: Positive Outcome of the PURETHAL Birch RUSH Study Results in an Approved, Accelerated up-dosing Regimen

May 12, 2013: Desentum: EARTO innovation prize to VTT

Mar 09, 2006: Stallergenes Reports Positive Study Results with Biomay's Bet v 1

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Birch Pollen Allergy, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

List of Tables

Number of Products under Development for Birch Pollen Allergy, H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Birch Pollen Allergy-Pipeline by ALK-Abello AS, H1 2019

Birch Pollen Allergy-Pipeline by Allergy Therapeutics Plc, H1 2019

Birch Pollen Allergy-Pipeline by Anergis SA, H1 2019

Birch Pollen Allergy-Pipeline by Biomay AG, H1 2019

Birch Pollen Allergy-Pipeline by Desentum Oy, H1 2019

Birch Pollen Allergy-Pipeline by HAL Allergy BV, H1 2019

Birch Pollen Allergy-Pipeline by Laboratorios LETI SL, H1 2019

Birch Pollen Allergy-Pipeline by S-TARget therapeutics GmbH, H1 2019

Birch Pollen Allergy-Dormant Projects, H1 2019

Birch Pollen Allergy-Discontinued Products, H1 2019

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

ALK-Abello AS

Allergy Therapeutics Plc

Anergis SA

Biomay AG

Desentum Oy

HAL Allergy BV

Laboratorios LETI SL

S-TARget therapeutics GmbH

Birch Pollen Allergy Therapeutic Products under Development, Key Players in Birch Pollen Allergy Therapeutics, Birch Pollen Allergy Pipeline Overview, Birch Pollen Allergy Pipeline, Birch Pollen Allergy Pipeline Assessment

select a license
Single User License
USD 2000 INR 140000
Site License
USD 4000 INR 280000
Corporate User License
USD 6000 INR 420000

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com